

August 10, 2022

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

TREASURE study results to be presented at the 14th World Stroke Congress

HEALIOS K.K. (“Healios”) announces that the results of the “TREASURE” study, its clinical trial conducted in Japan for ischemic stroke patients, will be presented in a plenary session at the 14th World Stroke Congress to be held in Singapore from October 26 to 29, 2022.

Date: October 26, 2022, 18:00-18:10 (local time)

[Plenary 01: Awards and Late Breaking](#)

Title: Results of the treatment evaluation of acute stroke using regenerative cells (TREASURE) clinical trial

Presenter: Toshiya Osanai, Ph.D, Hokkaido University, Department of Neurosurgery

Venue: Suntec Singapore Convention & Exhibition Center

Congress URL: <https://worldstrokecongress.org/>

About the TREASURE study

The TREASURE study was conducted to investigate the safety and efficacy of HLCM051 (Multistem®) in patients with ischemic stroke. The study targeted patients with moderate to moderate-severe strokes (baseline NIHSS score 8-20), with administration of a single dose of HLCM051 intravenously within 18-36 hours from stroke onset. The trial was conducted at 48 sites in Japan and enrolled 206 patients. HLCM051 is an off-the-shelf, somatic stem cell regenerative medicine product that Healios is developing for both ischemic stroke and acute respiratory distress syndrome in Japan.

Contact:
IR & Finance and Accounting Division, HEALIOS K.K.
E-mail: ir@healios.jp